Analysis of genetic factors in lung cancer
Molecular and Genetic Analysis of Lung Cancer
This study is trying to find out if certain genetic factors affect the risk of lung cancer and how well patients respond to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 15000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT03029325 on ClinicalTrials.gov |
What this trial studies
This observational study employs a genome-wide approach to identify single nucleotide polymorphisms (SNPs) associated with lung cancer risk and survival. It includes a case-control design, comparing individuals with pathology-proven primary lung cancer to healthy controls. The study also explores how genetic variants may influence treatment outcomes at different stages of the disease, aiming to uncover prognostic and predictive factors for patient survival.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of primary lung cancer or healthy individuals without any cancer.
Not a fit: Patients under 18 years old or those with other types of cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of genetic factors influencing lung cancer, potentially guiding personalized treatment strategies.
How similar studies have performed: Other studies have shown success in identifying genetic markers related to cancer risk and treatment outcomes, indicating that this approach has potential.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * healthy controls: participants without evidence of any cancer * cases: pathology proven primary lung cancer Exclusion Criteria: * younger than 18 years old
Where this trial is running
Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: David C Christiani, MD — Harvard TH Chan School of Public Health
- Study coordinator: David Christiani, MD
- Email: dchris@hsph.harvard.edu
- Phone: 617-726-9274
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.